Table 1: Clinicopathologic characteristics of the study population ().

Age at diagnosis, years (mean ± StD)66 ± 10.5

GenderMale: 50%
Female: 50%

Disease stage III (28%)
IV (72%)

Type of chemotherapyGemcitabine + Erlotinib

Clinical responsePR (14.29%)
SD (21.43%)
PD (64.28%

Survival time, months (mean ± StD)12.6 ± 12.6

Outcome:
 Follow-up months (mean ± StD)12.6 ± 12.6
 Death from pancreatic cancer 100%
 Alive 0%
 Lost to follow-up (censored cases)0%

CEA level [μg/L] (mean ± StD)2219 ± 5017
Healthy: 0–37

CA 19-9 level [U/L] (mean ± StD)899 ± 3185
Healthy: 0–5

PR: partial response; SD: stable disease; PD: progressive disease; StD: standard deviation.